NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for UTMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve EPS of about $0.82 in 2026 | The company expects to earn about $0.82 per share in 2026. | Intact | EPS falls below $0.82 in FY26 | Diluted EPS: $0.88 per share FY2026-Q3; GAAP. Published target: EPS >= $0.82 for fiscal year 2026. Annual target cannot be compared with a quarterly or TTM observation. Oct 22, 20260.88 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a small healthcare business with a recovery-and-execution thesis, rather than a clear, steady growth story. The thesis is intact, recent financial performance is strong relative to its industry, and management’s progress on key priorities is mixed.
The valuation evidence describes UTMD as cheap versus peers, with a modest expectations gap and no signs of fragile pricing. The valuation measure has risen recently, but the snapshot does not show that the market assumes a strong revenue recovery.
Near term, revenue remains under pressure: nine-month revenue was lower year over year, and management still projects a full-year sales decline close to 7%. Orion has begun contributing sales, while slower-than-expected biopharma sales and ongoing litigation costs remain obstacles; the earnings-miss risk is flagged as quiet, though consecutive misses are a concern.
The multi-year view depends on replacing lost customer sales, growing Orion’s contribution, and controlling litigation costs. Near term, a guidance cut or further job-market weakness would add risk, while strong results and guidance from healthcare peers would support the sector backdrop.
Over the next 1 to 3 years, UTMD’s thesis rests on whether management can turn early sales contributions into a sustained revenue recovery while limiting legal costs. The evidence is mixed, and overall confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Utah Medical Products, Inc.'s published investment case. The stated target is No OEM sales to PendoTech and no blood pressure kits to China in 2026. |
| Intact |
| Any OEM sales to PendoTech or blood pressure kits shipped to China in 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain consistent revenue aligned with projections | A primary condition in Utah Medical Products, Inc.'s published investment case. The stated target is Revenue remains at or above $8.72M per quarter. | Broken | Quarterly revenue falls below $8.72M in any quarter | Revenue: $8.621M FY2026-Q3; GAAP. Published target: Revenue remains at or above $8.72M per quarter. Target period is not explicitly aligned with this observation. Oct 22, 20268,621,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.